Compare Dover Corp (DOV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs TG Therapeutics Inc — how do they compare? Dover Corp trades at $207.57 (market cap $28.07B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Dover Corp is far larger — about 3.7× TG Therapeutics Inc's market cap, and Dover Corp pays a 1.01% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DOV | TGTX | |
|---|---|---|
Market Cap | $28.07B | $7.64B |
Sector | Industrials | Health |
52-Week High | $233.31 | $59.06 |
52-Week Low | $161.16 | $26.94 |
Enterprise Value | $29.58B | $7.84B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $208.07, down 0.97% on the day, with strong analyst support showing 19 buy ratings and a $232.33 consensus price target. The company demonstrates solid fundamentals with consistent earnings beats, a 13.48% net income margin, and recent dividend increases. Technical indicators show a bearish short-term signal despite neutral oscillators, with key support at $205.
DOV presents a compelling investment case with strong profitability, dividend growth, and raised 2026 guidance, though near-term technical weakness and acquisition integration risks warrant monitoring. The stock offers approximately 11.7% upside to analyst targets with no sell ratings among 28 covering firms.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
